

Psychedelic Medicine-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

<https://marketpublishers.com/r/P39531876115EN.html>

Date: December 2021

Pages: 133

Price: US\$ 3,680.00 (Single User License)

ID: P39531876115EN

Abstracts

Report Summary

Psychedelic Medicine-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on Psychedelic Medicine industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Psychedelic Medicine 2016-2021, and development forecast 2022-2026

Main manufacturers/suppliers of Psychedelic Medicine worldwide and market share by regions, with company and product introduction, position in the Psychedelic Medicine market

Market status and development trend of Psychedelic Medicine by types and applications

Cost and profit status of Psychedelic Medicine, and marketing status

Market growth drivers and challenges Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Psychedelic Medicine market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all

indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Psychedelic Medicine industry.

The report segments the global Psychedelic Medicine market as:

Global Psychedelic Medicine Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)

Middle East and Africa

Global Psychedelic Medicine Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):

Psilocybin

LSD

MDMA

DMT

Ketamine

Others

Global Psychedelic Medicine Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)

Depressive Disorders

Post-Traumatic Stress Disorders

Substance Abuse Disorders

Obsessive Compulsive Disorders

Others

Global Psychedelic Medicine Market: Manufacturers Segment Analysis (Company and Product introduction, Psychedelic Medicine Sales Volume, Revenue, Price and Gross Margin):

COMPASS Pathways PLC

Pfizer

Eli Lilly

GlaxoSmithKline

Cybin Inc
Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Janssen
Acadia Pharmaceuticals
Intellipharmaceuticals
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF PSYCHEDELIC MEDICINE

- 1.1 Definition of Psychedelic Medicine in This Report
- 1.2 Commercial Types of Psychedelic Medicine
 - 1.2.1 Psilocybin
 - 1.2.2 LSD
 - 1.2.3 MDMA
 - 1.2.4 DMT
 - 1.2.5 Ketamine
 - 1.2.6 Others
- 1.3 Downstream Application of Psychedelic Medicine
 - 1.3.1 Depressive Disorders
 - 1.3.2 Post-Traumatic Stress Disorders
 - 1.3.3 Substance Abuse Disorders
 - 1.3.4 Obsessive Compulsive Disorders
 - 1.3.5 Others
- 1.4 Development History of Psychedelic Medicine
- 1.5 Market Status and Trend of Psychedelic Medicine 2016-2026
 - 1.5.1 Global Psychedelic Medicine Market Status and Trend 2016-2026
 - 1.5.2 Regional Psychedelic Medicine Market Status and Trend 2016-2026

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Psychedelic Medicine 2016-2021
- 2.2 Sales Market of Psychedelic Medicine by Regions
 - 2.2.1 Sales Volume of Psychedelic Medicine by Regions
 - 2.2.2 Sales Value of Psychedelic Medicine by Regions
- 2.3 Production Market of Psychedelic Medicine by Regions
- 2.4 Global Market Forecast of Psychedelic Medicine 2022-2026
 - 2.4.1 Global Market Forecast of Psychedelic Medicine 2022-2026
 - 2.4.2 Market Forecast of Psychedelic Medicine by Regions 2022-2026

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Psychedelic Medicine by Types
- 3.2 Sales Value of Psychedelic Medicine by Types
- 3.3 Market Forecast of Psychedelic Medicine by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of Psychedelic Medicine by Downstream Industry
- 4.2 Global Market Forecast of Psychedelic Medicine by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America Psychedelic Medicine Market Status by Countries
 - 5.1.1 North America Psychedelic Medicine Sales by Countries (2016-2021)
 - 5.1.2 North America Psychedelic Medicine Revenue by Countries (2016-2021)
 - 5.1.3 United States Psychedelic Medicine Market Status (2016-2021)
 - 5.1.4 Canada Psychedelic Medicine Market Status (2016-2021)
 - 5.1.5 Mexico Psychedelic Medicine Market Status (2016-2021)
- 5.2 North America Psychedelic Medicine Market Status by Manufacturers
- 5.3 North America Psychedelic Medicine Market Status by Type (2016-2021)
 - 5.3.1 North America Psychedelic Medicine Sales by Type (2016-2021)
 - 5.3.2 North America Psychedelic Medicine Revenue by Type (2016-2021)
- 5.4 North America Psychedelic Medicine Market Status by Downstream Industry (2016-2021)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe Psychedelic Medicine Market Status by Countries
 - 6.1.1 Europe Psychedelic Medicine Sales by Countries (2016-2021)
 - 6.1.2 Europe Psychedelic Medicine Revenue by Countries (2016-2021)
 - 6.1.3 Germany Psychedelic Medicine Market Status (2016-2021)
 - 6.1.4 UK Psychedelic Medicine Market Status (2016-2021)
 - 6.1.5 France Psychedelic Medicine Market Status (2016-2021)
 - 6.1.6 Italy Psychedelic Medicine Market Status (2016-2021)
 - 6.1.7 Russia Psychedelic Medicine Market Status (2016-2021)
 - 6.1.8 Spain Psychedelic Medicine Market Status (2016-2021)
 - 6.1.9 Benelux Psychedelic Medicine Market Status (2016-2021)
- 6.2 Europe Psychedelic Medicine Market Status by Manufacturers
- 6.3 Europe Psychedelic Medicine Market Status by Type (2016-2021)
 - 6.3.1 Europe Psychedelic Medicine Sales by Type (2016-2021)

- 6.3.2 Europe Psychedelic Medicine Revenue by Type (2016-2021)
- 6.4 Europe Psychedelic Medicine Market Status by Downstream Industry (2016-2021)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Psychedelic Medicine Market Status by Countries
 - 7.1.1 Asia Pacific Psychedelic Medicine Sales by Countries (2016-2021)
 - 7.1.2 Asia Pacific Psychedelic Medicine Revenue by Countries (2016-2021)
 - 7.1.3 China Psychedelic Medicine Market Status (2016-2021)
 - 7.1.4 Japan Psychedelic Medicine Market Status (2016-2021)
 - 7.1.5 India Psychedelic Medicine Market Status (2016-2021)
 - 7.1.6 Southeast Asia Psychedelic Medicine Market Status (2016-2021)
 - 7.1.7 Australia Psychedelic Medicine Market Status (2016-2021)
- 7.2 Asia Pacific Psychedelic Medicine Market Status by Manufacturers
- 7.3 Asia Pacific Psychedelic Medicine Market Status by Type (2016-2021)
 - 7.3.1 Asia Pacific Psychedelic Medicine Sales by Type (2016-2021)
 - 7.3.2 Asia Pacific Psychedelic Medicine Revenue by Type (2016-2021)
- 7.4 Asia Pacific Psychedelic Medicine Market Status by Downstream Industry (2016-2021)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Psychedelic Medicine Market Status by Countries
 - 8.1.1 Latin America Psychedelic Medicine Sales by Countries (2016-2021)
 - 8.1.2 Latin America Psychedelic Medicine Revenue by Countries (2016-2021)
 - 8.1.3 Brazil Psychedelic Medicine Market Status (2016-2021)
 - 8.1.4 Argentina Psychedelic Medicine Market Status (2016-2021)
 - 8.1.5 Colombia Psychedelic Medicine Market Status (2016-2021)
- 8.2 Latin America Psychedelic Medicine Market Status by Manufacturers
- 8.3 Latin America Psychedelic Medicine Market Status by Type (2016-2021)
 - 8.3.1 Latin America Psychedelic Medicine Sales by Type (2016-2021)
 - 8.3.2 Latin America Psychedelic Medicine Revenue by Type (2016-2021)
- 8.4 Latin America Psychedelic Medicine Market Status by Downstream Industry (2016-2021)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa Psychedelic Medicine Market Status by Countries
 - 9.1.1 Middle East and Africa Psychedelic Medicine Sales by Countries (2016-2021)
 - 9.1.2 Middle East and Africa Psychedelic Medicine Revenue by Countries (2016-2021)
 - 9.1.3 Middle East Psychedelic Medicine Market Status (2016-2021)
 - 9.1.4 Africa Psychedelic Medicine Market Status (2016-2021)
- 9.2 Middle East and Africa Psychedelic Medicine Market Status by Manufacturers
- 9.3 Middle East and Africa Psychedelic Medicine Market Status by Type (2016-2021)
 - 9.3.1 Middle East and Africa Psychedelic Medicine Sales by Type (2016-2021)
 - 9.3.2 Middle East and Africa Psychedelic Medicine Revenue by Type (2016-2021)
- 9.4 Middle East and Africa Psychedelic Medicine Market Status by Downstream Industry (2016-2021)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF PSYCHEDELIC MEDICINE

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Psychedelic Medicine Downstream Industry Situation and Trend Overview

CHAPTER 11 PSYCHEDELIC MEDICINE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of Psychedelic Medicine by Major Manufacturers
- 11.2 Production Value of Psychedelic Medicine by Major Manufacturers
- 11.3 Basic Information of Psychedelic Medicine by Major Manufacturers
 - 11.3.1 Headquarters Location and Established Time of Psychedelic Medicine Major Manufacturer
 - 11.3.2 Employees and Revenue Level of Psychedelic Medicine Major Manufacturer
- 11.4 Market Competition News and Trend
 - 11.4.1 Merger, Consolidation or Acquisition News
 - 11.4.2 Investment or Disinvestment News
 - 11.4.3 New Product Development and Launch

CHAPTER 12 PSYCHEDELIC MEDICINE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 12.1 COMPASS Pathways PLC
 - 12.1.1 Company profile
 - 12.1.2 Representative Psychedelic Medicine Product

12.1.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of COMPASS Pathways PLC

12.2 Pfizer

12.2.1 Company profile

12.2.2 Representative Psychedelic Medicine Product

12.2.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of Pfizer

12.3 Eli Lilly

12.3.1 Company profile

12.3.2 Representative Psychedelic Medicine Product

12.3.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of Eli Lilly

12.4 GlaxoSmithKline

12.4.1 Company profile

12.4.2 Representative Psychedelic Medicine Product

12.4.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of

GlaxoSmithKline

12.5 Cybin Inc

12.5.1 Company profile

12.5.2 Representative Psychedelic Medicine Product

12.5.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of Cybin Inc

12.6 Field Trip Health

12.6.1 Company profile

12.6.2 Representative Psychedelic Medicine Product

12.6.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of Field Trip

Health

12.7 ATAI Life Sciences

12.7.1 Company profile

12.7.2 Representative Psychedelic Medicine Product

12.7.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of ATAI Life

Sciences

12.8 NUMINUS WELLNESS

12.8.1 Company profile

12.8.2 Representative Psychedelic Medicine Product

12.8.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of NUMINUS

WELLNESS

12.9 MindMed

12.9.1 Company profile

12.9.2 Representative Psychedelic Medicine Product

12.9.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of MindMed

12.10 HAVN Life Sciences

- 12.10.1 Company profile
- 12.10.2 Representative Psychedelic Medicine Product
- 12.10.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of HAVN Life Sciences
- 12.11 Seelos Therapeutics
 - 12.11.1 Company profile
 - 12.11.2 Representative Psychedelic Medicine Product
 - 12.11.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of Seelos Therapeutics
- 12.12 Janssen
 - 12.12.1 Company profile
 - 12.12.2 Representative Psychedelic Medicine Product
 - 12.12.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of Janssen
- 12.13 Acadia Pharmaceuticals
 - 12.13.1 Company profile
 - 12.13.2 Representative Psychedelic Medicine Product
 - 12.13.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of Acadia Pharmaceuticals
- 12.14 Intellipharmaeueutics
 - 12.14.1 Company profile
 - 12.14.2 Representative Psychedelic Medicine Product
 - 12.14.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of Intellipharmaeueutics
- 12.15 Revive Therapeutics
 - 12.15.1 Company profile
 - 12.15.2 Representative Psychedelic Medicine Product
 - 12.15.3 Psychedelic Medicine Sales, Revenue, Price and Gross Margin of Revive Therapeutics
- 12.16 Mydecine Innovations Group
- 12.17 Red Light Holland
- 12.18 Braxia Scientific
- 12.19 Mind Cure Health
- 12.20 Entheon Biomedical

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PSYCHEDELIC MEDICINE

- 13.1 Industry Chain of Psychedelic Medicine
- 13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF PSYCHEDELIC MEDICINE

- 14.1 Cost Structure Analysis of Psychedelic Medicine
- 14.2 Raw Materials Cost Analysis of Psychedelic Medicine
- 14.3 Labor Cost Analysis of Psychedelic Medicine
- 14.4 Manufacturing Expenses Analysis of Psychedelic Medicine

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

- 16.1 Methodology/Research Approach
 - 16.1.1 Research Programs/Design
 - 16.1.2 Market Size Estimation
 - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
 - 16.2.1 Secondary Sources
 - 16.2.2 Primary Sources
- 16.3 Reference

I would like to order

Product name: Psychedelic Medicine-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/P39531876115EN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P39531876115EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

